Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MergersSEC EDGAR SCHEDULE 13GFiled 25 h ago

Oaktree Acquisition Corp. III Life Sciences: Decagon Asset Management LLP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Decagon Asset Management LLP amended its Schedule 13G filing on Oaktree Acquisition Corp. III Life Sciences, disclosing a change in its beneficial ownership stake in the special purpose acquisition company. The update was filed with the SEC under accession number 0001950677-26-000036. The filing signals a shift in Decagon's position in the life sciences-focused SPAC, which is sponsored by Oaktree and targets healthcare investments. Investors should watch for further 13G or 13D amendments to gauge whether Decagon's stake change reflects passive portfolio rebalancing or a more active stance ahead of any potential business combination.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Decagon Asset Management LLP, Oaktree Acquisition Corp. III Life Sciences